Department of
Dr. Jose Moron-Concepcion, a professor at Washington University School of Medicine in St. Louis, has been appointed to the National Advisory Dental and Craniofacial Research Council for a four-year term, advising on matters related to dental and craniofacial research, with a focus on opioid addiction and pain research.
We are thrilled to announce the incoming 2023 cohort of Anesthesiology Summer Research (ASSURE) fellows, marking the third year of the program at the Washington University School of Medicine in St. Louis.
In a study published in Nature Communications in March 2023, researchers from the Center for Clinical Pharmacology unveil promising research in the development of more effective, less addictive, and safer pain management drugs.
On March 3, 2023, several clinicians and staff members from the Department of Anesthesiology presented at the 13th Annual Patient Safety & Quality Symposium.
According to the latest data compiled by the Blue Ridge Institute for Medical Research, the Department of Anesthesiology at Washington University School of Medicine in St. Louis ranked No. 3 among the nation’s top anesthesiology departments in terms of research funding from the National Institutes of Health (NIH).
Scientists at Washington University School of Medicine in St. Louis were awarded $569 million in research grants from the National Institutes of Health (NIH) in federal fiscal year 2022, elevating WashU to No. 3 among U.S. medical schools in total NIH research funding support.
Brandon Tan, MD, PGY5 and an ASAP trainee, has been selected as one of the 2023 Dean’s Scholars. His project explores how the serotonin 3 receptor—implicated in nausea, depression, anxiety, and psychosis—changes its activity when the lipid environment is altered.
The Department of Anesthesiology is delighted to announce that Burel R. Goodin, PhD, is joining Washington University School of Medicine as professor of anesthesiology March 1, 2023.
A research team, led by scientists at the Center for Clinical Pharmacology at Washington University School of Medicine and the University of Health Sciences & Pharmacy in St. Louis, have altered the chemical properties of fentanyl and the way that it binds to opioid receptors on nerve cells. The goal is to improve the drug’s safety profile without eliminating its ability to alleviate pain.
The paper highlights the work of Susruta Majumdar, Ph.D., associate professor of medicinal chemistry and pharmacology at University of Health Sciences and Pharmacy in St. Louis, and his colleagues who examined the molecular differences between LFT and MP, and how they bind to MU opioid receptors.